Procter & Gamble Hygiene
and Health Care Limited
CIN: L24239MH1964PLC012971
Registered Office:
P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
Tel: (91-22) 6958 6000
Fax: (91-22) 6958 7337
Website: in.pg.com

July 29, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Ref:- Scrip Code:- 500459

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Scrip Code:- PGHH

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended June 30, 2026

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today i.e. July 29, 2026, (commenced at 11:56 A.M. and ended at 12:45 P.M.), the Unaudited Financial Results for the quarter ended June 30, 2026 were approved.

We are enclosing herewith the following:

a. Unaudited Financial Results for the quarter ended June 30, 2026; and
b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended June 30, 2026, furnished by Statutory Auditors of the Company.

Kindly take the same on record.

Thanking you,
Yours faithfully,

For **Procter & Gamble Hygiene and Health Care Limited**

Flavia Peter Machado
Flavia Peter Machado
2026.07.29
12:47:51 +05'30'

Flavia Machado
Authorized Signatory

KALYANIWALLA
& MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT
TO THE BOARD OF DIRECTORS
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of ***PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED*** ("the Company") for the quarter ended June 30, 2026, and the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification. This Statement which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

4. Attention is drawn to the fact that the figures for the three months ended March 31, 2026, as reported in the Statement, are the balancing figures between the audited figures in respect of the full previous financial year and the published year to date figures up to the end of the third quarter of the previous financial year, which have been reviewed and not subjected to audit by us.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Reg. No.: 104607W / W100166

DZFraser

Daraius Z. Fraser
PARTNER
M. No. 042454
UDIN: 26042454DZINTR8486
Mumbai: July 29, 2026.

Procter & Gamble Hygiene and Health Care Limited
CIN : L24239MH1964PLC012971
Registered Office: P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
Tel: (91 – 22) 6958 6000
Fax: (91 – 22) 6958 7337
Website: in.pg.com

(₹ in Lakhs)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

	Particulars	(1) Three Months Ended 30th June 2026	(2) Preceding Three Months Ended 31st March 2026	(3) Corresponding Three Months Ended 30th June 2025	(4) Previous Year Ended 31st March 2026
		(Unaudited)	(Audited) (Refer Note 5 below)	(Unaudited)	(Audited)
1	**Income**				
	Sale of products	88 992	93 767	93 516	4 28 159
	Other operating revenues	154	365	187	883
2	**Revenue from operations**	**89 146**	**94 132**	**93 703**	**4 29 042**
3	Other income	943	1 247	769	4 247
	Total income (2+3)	**90 089**	**95 379**	**94 472**	**4 33 289**
4	**Expenses**				
a)	Cost of raw and packing materials consumed	20 024	17 068	16 440	73 811
b)	Purchases of stock-in-trade (Traded goods)	21 323	19 324	20 248	82 396
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3 322)	(711)	(2 571)	308
d)	Employee benefits expense	5 436	5 653	4 835	21 514
e)	Finance costs	27	311	7	945
f)	Depreciation and amortization expense	959	956	909	3 743
g)	Advertising & sales promotion expenses	8 332	13 254	6 873	52 272
h)	Other expenses	20 347	17 713	21 261	81 637
	Total expenses	**73 126**	**73 568**	**68 002**	**3 16 626**
5	**Profit before tax (2+3-4)**	**16 963**	**21 811**	**26 470**	**1 16 663**
6	**Income tax expense**				
a)	Current tax	4 389	5 703	6 662	29 995
b)	Deferred tax	(53)	785	80	632
c)	Prior year tax adjustments	—	10	522	386
		4 336	**6 498**	**7 264**	**31 013**
7	**Profit for the period (5-6)**	**12 627**	**15 313**	**19 206**	**85 650**
8	**Other comprehensive income / (loss)**				
	Items that will not be reclassified to profit or loss				
	Remeasurement of the defined benefit plans	143	92	(236)	573
	Income tax effect on above	(36)	(23)	59	(144)
	Total other comprehensive income / (loss) for the period	**107**	**69**	**(177)**	**429**
9	**Total comprehensive income for the period (7+8)**	**12 734**	**15 382**	**19 029**	**86 079**
10	Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246
11	Other Equity				72 101
12	**Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :**				
a)	Basic (in ₹)	38.90	47.17	59.17	263.86
b)	Diluted (in ₹)	38.90	47.17	59.17	263.86
	See accompanying notes to the financial results				

KALYANIWALLA & MISTRY LLP ★ MUMBAI

Notes:

1 The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 29th July, 2026 and have been subjected to a limited review by the Statutory Auditors of the Company. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2 The Unaudited Financial Results are prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS-34), as prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.

3 The Company's operating segments under Ind AS 108 – Operating Segments are as follows:
- Health Care Products – Comprising of Ointment and Creams, Cough Drops and Tablets.
- Hygiene Products - Comprising of Feminine Hygiene products and other skin care hygiene.

These individual operating segments have been aggregated into a single primary reportable segment i.e. manufacturing, trading and marketing of Health and Hygiene Products in accordance with Ind AS 108-Operating Segments. Accordingly, no separate segment information has been provided.

4 The Company does not have a subsidiary, associate or a joint venture as at June 30, 2026.

5 The figures of the preceding three months ended March 31, 2026, are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026, and the published year to date figures up to the third quarter of that financial year.

For and on behalf of the Board of Directors of
Procter & Gamble Hygiene and Health Care Limited

KUMAR VENKATASUBRAMANIAN
KUMAR VENKATASUBRAMANIAN
2026.07.29 12:13:54 +05'30'

Kumar Venkatasubramanian
Managing Director

Place: Mumbai
Date: July 29, 2026

KALYANIWALLA & MISTRY LLP * MUMBAI